BR0206361A - Método de terapia de reposição de hormÈnio e sua forma de administração - Google Patents

Método de terapia de reposição de hormÈnio e sua forma de administração

Info

Publication number
BR0206361A
BR0206361A BR0206361-1A BR0206361A BR0206361A BR 0206361 A BR0206361 A BR 0206361A BR 0206361 A BR0206361 A BR 0206361A BR 0206361 A BR0206361 A BR 0206361A
Authority
BR
Brazil
Prior art keywords
hormone
administration
daily
ingestion
period
Prior art date
Application number
BR0206361-1A
Other languages
English (en)
Inventor
Hermann Kulmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0206361A publication Critical patent/BR0206361A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODO DE TERAPIA DE REPOSIçãO DE HORMÈNIO E SUA FORMA DE ADMINISTRAçãO". A invenção refere-se a um método para terapia de reposição de hormónio, em que pelo menos na pós-menopausa estabelecida uma unidade diária com pelo menos um componente hormonal, a saber com pelo menos estrogênio (E) e/ou pelo menos um gestágeno (G) é administrado permanentemente e continuamente a cada dia, caracterizado pelo fato de que em pelo menos um período de ingestão que precede a administração permanente de unidades diárias de hormónio é provido uma pausa de ingestão (P), em que ou nenhuma unidade diária ou placebos ou unidades diárias com um teor de estrogênio e/ou gestágeno muito menor do que durante a administração permanente de unidades diárias de hormónio na pós-menopausa estabelecida e durante a(s) fase(s) de ingestão do período de ingestão precedente são administradas, bem como forma de administração para terapia de hormónio.
BR0206361-1A 2001-01-11 2002-01-08 Método de terapia de reposição de hormÈnio e sua forma de administração BR0206361A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10100911A DE10100911A1 (de) 2001-01-11 2001-01-11 Verfahren zur Hormonersatztherapie und dessen Darreichungsform
PCT/EP2002/000089 WO2002055086A2 (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form

Publications (1)

Publication Number Publication Date
BR0206361A true BR0206361A (pt) 2004-02-17

Family

ID=7670195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206361-1A BR0206361A (pt) 2001-01-11 2002-01-08 Método de terapia de reposição de hormÈnio e sua forma de administração

Country Status (21)

Country Link
US (1) US7871994B2 (pt)
EP (1) EP1372665B1 (pt)
JP (1) JP2004525883A (pt)
AR (1) AR033413A1 (pt)
AT (1) ATE348620T1 (pt)
AU (1) AU2007202118A1 (pt)
BR (1) BR0206361A (pt)
CA (1) CA2433656A1 (pt)
CY (1) CY1106374T1 (pt)
DE (2) DE10100911A1 (pt)
DK (1) DK1372665T3 (pt)
ES (1) ES2278896T3 (pt)
IL (1) IL156655A0 (pt)
MX (1) MXPA03006157A (pt)
NO (1) NO20033155L (pt)
NZ (1) NZ539581A (pt)
PE (1) PE20020795A1 (pt)
PT (1) PT1372665E (pt)
UY (1) UY27117A1 (pt)
WO (1) WO2002055086A2 (pt)
ZA (1) ZA200306120B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495330A1 (en) * 2002-08-28 2004-03-11 Robert Casper Estrogen replacement regimen
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
PT1558265E (pt) * 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
ES2482104T3 (es) 2003-09-29 2014-08-01 Novo Nordisk Femcare Ag Formulaciones HRT
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4405590C1 (de) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonbehandlung
DE4405591C1 (de) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution
DE19513662A1 (de) 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19539233A1 (de) 1995-10-21 1997-04-24 Klaus Dr Med Umbreit Oral einzunehmendes ovulationshemmendes Mittel

Also Published As

Publication number Publication date
CA2433656A1 (en) 2002-07-18
IL156655A0 (en) 2004-01-04
DE10100911A1 (de) 2002-08-01
PT1372665E (pt) 2007-03-30
DE60216899D1 (de) 2007-02-01
AR033413A1 (es) 2003-12-17
NZ539581A (en) 2007-07-27
MXPA03006157A (es) 2003-09-16
CY1106374T1 (el) 2011-10-12
DK1372665T3 (da) 2007-04-30
UY27117A1 (es) 2002-07-31
NO20033155D0 (no) 2003-07-10
EP1372665B1 (en) 2006-12-20
ZA200306120B (en) 2004-09-08
EP1372665A2 (en) 2004-01-02
ATE348620T1 (de) 2007-01-15
WO2002055086A2 (en) 2002-07-18
DE60216899T2 (de) 2007-10-25
AU2007202118A1 (en) 2007-05-31
NO20033155L (no) 2003-09-10
US20040106586A1 (en) 2004-06-03
US7871994B2 (en) 2011-01-18
WO2002055086A3 (en) 2003-10-16
JP2004525883A (ja) 2004-08-26
ES2278896T3 (es) 2007-08-16
PE20020795A1 (es) 2002-10-03

Similar Documents

Publication Publication Date Title
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
BRPI0410645A (pt) derivados de aril-carbaldeìdo oxima e sua aplicação como agentes estrogênicos
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
HUP0301042A2 (hu) Fogamzásgátlásra használható gyógyszerkészítmény
ATE213947T1 (de) Progestogen-anti-progestogen therapien
DK0767798T3 (da) Sterolderivater anvendt til regulering af meiose
BR0211336A (pt) Métodos para o tratamento da fibrose do fìgado
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BR9913681A (pt) Composição farmacêutica compreendendo entacapona ou nitecapona, assim como um derivado de celulose reticulada
AP2001002054A0 (en) Use of biogenic estrogen sulfamates for hormone replacement therapy.
BR0206361A (pt) Método de terapia de reposição de hormÈnio e sua forma de administração
MY117307A (en) New harmone medicaments and their use for correction of oestrogen deficiencies.
BR0009728A (pt) Métodos para estabilização de produtos lìquidos nutricionais e produtos assim estabilizados
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
BR0202155A (pt) Método para a aplicação nasal de substância medicinal
TW200500079A (en) Compositions and methods for treating coronavirus infection and sars
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio
BRPI0415051A (pt) compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas
BR9811422A (pt) Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.